Clinical evidence summaries for type 2 diabetes, including glycaemic therapies, cardiovascular outcomes, kidney protection, complications, technology, obesity, and long-term safety.
An OPTION post-hoc analysis finds indobufen-based antiplatelet therapy after stenting performs consistently regardless of diabetes status, with a similar bleeding advantage. PICO summary and commentary.
A phase-3 secondary analysis finds enavogliflozin lowers leptin independent of weight in type 2 diabetes, while the adiponectin rise was weight-dependent. PICO summary and commentary.
A cross-sectional study finds ultra-processed food intake is not linked to glucose or body size in type 2 diabetes, but is associated with higher LDL cholesterol. PICO summary and commentary.
A pilot crossover study finds single- and multi-joint resistance exercise both lower glucose acutely in type 2 diabetes, but neither beats a no-exercise control. PICO summary and commentary.
An RCT finds an eight-session lifestyle health-promotion programme improves health behaviours and beliefs in type 2 diabetes, on self-report measures. PICO summary and commentary.
A prespecified DARE-19 analysis found dapagliflozin was safe and well tolerated in hospitalised COVID-19 patients regardless of type 2 diabetes status, with no demonstrated efficacy benefit. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
